Literature DB >> 26381291

DUSP16 ablation arrests the cell cycle and induces cellular senescence.

Haibin Zhang1, Hai Zheng2,3, Wenjing Mu2, Zhiying He4, Bo Yang5, Yuan Ji6, Lijian Hui2.   

Abstract

Dual-specificity phosphatases (DUSPs) are a family of protein phosphatases that dephosphorylate both phosphotyrosine and phosphoserine/phosphothreonine residues. DUSPs are de-regulated in many human diseases, including cancers. However, the function of DUSPs in tumorigenesis remains largely unknown. Here, using short hairpin RNA-based gene knockdown, we found that several members of the DUSP family play critical roles in regulating cell proliferation. In particular, we showed that DUSP16 ablation leads to a G1/S transition arrest, reduced incorporation of 5-bromodeoxyuridine, enhanced senescence-associated β-galactosidase activity, and formation of senescence-associated heterochromatic foci. Mechanistically, DUSP16 silencing causes cellular senescence by activating the tumor suppressors p53 and Rb. The phosphatase activity of DUSP16 is necessary for antagonizing cellular senescence. Importantly, the expression levels of DUSP16 are up-regulated in human liver cancers, and are positively correlated with tumor cell proliferation. Taken together, our findings indicate that DUSP16 plays a role in tumorigenesis by protecting cancer cells from senescence.
© 2015 FEBS.

Entities:  

Keywords:  DUSP16; Rb; liver cancer; p53; senescence

Mesh:

Substances:

Year:  2015        PMID: 26381291     DOI: 10.1111/febs.13518

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  7 in total

Review 1.  Role of the IL-33/ST2 receptor axis in ovarian cancer progression.

Authors:  Ning Liu; Jintong Chen; Yinghua Zhao; Mingyue Zhang; Li Piao; Siqing Wang; Ying Yue
Journal:  Oncol Lett       Date:  2021-04-29       Impact factor: 2.967

2.  Dusp16 Deficiency Causes Congenital Obstructive Hydrocephalus and Brain Overgrowth by Expansion of the Neural Progenitor Pool.

Authors:  Ksenija Zega; Vukasin M Jovanovic; Zagorka Vitic; Magdalena Niedzielska; Laura Knaapi; Marin M Jukic; Juha Partanen; Roland H Friedel; Roland Lang; Claude Brodski
Journal:  Front Mol Neurosci       Date:  2017-11-09       Impact factor: 5.639

3.  Alterations of microRNAs and their predicted targeting mRNAs expression in RAW264.7 macrophages infected with Omp25 mutant Brucella melitensis.

Authors:  Huapei Zhu; Hanwei Jiao; Xin Nie; Baobao Li; Kailian Xu; Feng Pang; Ruiyong Cao; Shu Zhu; Xiaojian Yang; Zhenxing Zhang; Dongmei Peng; Yaying Li; Guohua Li; Haifeng Huang; Chuangfu Chen; Li Du; Fengyang Wang
Journal:  Innate Immun       Date:  2018-08-09       Impact factor: 2.680

Review 4.  Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma.

Authors:  Peng Liu; Qinghe Tang; Miaomiao Chen; Wenjian Chen; Yanli Lu; Zhongmin Liu; Zhiying He
Journal:  Front Oncol       Date:  2020-11-27       Impact factor: 6.244

5.  circRNA_0001679/miR-338-3p/DUSP16 axis aggravates acute lung injury.

Authors:  Jiang Zhu; Fukuan Zhong; Futao Chen; Yang Yang; Yingying Liao; Lifeng Cao; Yong Zhou; Qiaohong Bai
Journal:  Open Med (Wars)       Date:  2022-02-28

6.  CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.

Authors:  Graziana Digiacomo; Claudia Fumarola; Silvia La Monica; Mara Bonelli; Andrea Cavazzoni; Maricla Galetti; Rita Terenziani; Kamal Eltayeb; Francesco Volta; Silvia Zoppi; Patrizia Bertolini; Gabriele Missale; Roberta Alfieri; Pier Giorgio Petronini
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

7.  Integrative omics provide biological and clinical insights into acute respiratory distress syndrome.

Authors:  Mulong Du; Joe G N Garcia; Jason D Christie; Junyi Xin; Guoshuai Cai; Nuala J Meyer; Zhaozhong Zhu; Qianyu Yuan; Zhengdong Zhang; Li Su; Sipeng Shen; Xuesi Dong; Hui Li; John N Hutchinson; Paula Tejera; Xihong Lin; Meilin Wang; Feng Chen; David C Christiani
Journal:  Intensive Care Med       Date:  2021-05-25       Impact factor: 41.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.